IP Library › Granted Patent US 8,940,878
Granted Patent B2
US 8,940,878 · App. 12/822,990 · Granted Jan 27, 2015

Capture purification processes for proteins expressed in a non-mammalian system

Inventors: Joseph Edward Shultz (Santa Rosa Valley, CA); Roger Hart (Loveland, CO)
Assignee: Amgen Inc.
C07K1/22C07K1/145C07K1/18C07K1/32
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,940,878
App. No.
12/822,990
Granted
Jan 27, 2015
Kind
B2
Abstract

Methods of purifying proteins expressed in non-mammalian expression systems in a non-native soluble form directly from cell lysate are disclosed. Methods of purifying proteins expressed in non-mammalian expression systems in a non-native limited solubility form directly from a refold solution are also disclosed. Resin regeneration methods are also provided.

Claims (43)

1. A method of purifying a protein expressed in a non-native soluble form in a non-mammalian expression system comprising:

(a) lysing a non-mammalian cell in which the protein is expressed in a non-native soluble form to generate a cell lysate;

(b) contacting the cell lysate with a separation matrix under conditions suitable for the protein to associate with the separation matrix;

(c) washing the separation matrix; and

(d) eluting the protein from the separation matrix, wherein the separation matrix is an affinity resin selected from the group consisting of Protein A, Protein G and a synthetic mimetic affinity resin.

2. The method of claim 1 , wherein the protein is a complex protein.

3. The method of claim 2 , wherein the complex protein is selected from the group consisting of a multimeric protein, an antibody and an Fc fusion protein.

4. The method of claim 1 , wherein the non-mammalian expression system comprises bacteria or yeast cells.

5. The method of claim 1 , wherein the cell lysate is filtered before it is contacted with the separation matrix.

6. The method of claim 1 , further comprising refolding the protein to its native form after it is eluted.

7. A method of purifying a protein expressed in a non-native limited solubility form in a non-mammalian expression system comprising:

(a) expressing a protein in a non-native limited solubility form in a non-mammalian cell;

(b) lysing a non-mammalian cell;

(c) solubilizing the expressed protein in a solubilization solution comprising one or more of the following:

(i) a denaturant;

(ii) a reductant; and

(iii) a surfactant;

(d) forming a refold solution comprising the solubilization solution and a refold buffer, the refold buffer comprising one or more of the following:

(i) a denaturant;

(ii) an aggregation suppressor;

(iii) a protein stabilizer; and

(iv) a redox component;

(e) directly applying the refold solution to a separation matrix under conditions suitable for the protein to associate with the matrix;

(f) washing the separation matrix; and

(g) eluting the protein from the separation matrix, wherein the separation matrix is a non-affinity resin selected from the group consisting of ion exchange, mixed mode, and a hydrophobic interaction resin.

8. The method of claim 7 , wherein the non-native limited solubility form is a component of an inclusion body.

9. The method of claim 7 , wherein the protein is a complex protein.

10. The method of claim 7 , wherein the complex protein is selected from the group consisting of a multimeric protein, an antibody, a peptibody, and an Fc fusion protein.

11. The method of claim 7 , wherein the non-mammalian expression system is bacteria or yeast cells.

12. The method of claim 7 , wherein the denaturant of the solubilization solution or the refold buffer comprises one or more of urea, guanidinium salts, dimethyl urea, methylurea and ethylurea.

13. The method of claim 7 , wherein the reductant comprises one or more of cysteine, dithiothreitol (DTT), beta-mercaptoethanol and glutathione.

14. The method of claim 7 , wherein the surfactant comprises one or more of sarcosyl and sodium dodecylsulfate.

15. The method of claim 7 , wherein the aggregation suppressor is selected from the group consisting of arginine, proline, polyethylene glycols, non-ionic surfactants, ionic surfactants, polyhydric alcohols, glycerol, sucrose, sorbitol, glucose, Tris, sodium sulfate, potassium sulfate and osmolytes.

16. The method of claim 7 , wherein the protein stabilizer comprises one or more of arginine, proline, polyethylene glycols, non-ionic surfactants, ionic surfactants, polyhydric alcohols, glycerol, sucrose, sorbitol, glucose, tris, sodium sulfate, potassium sulfate and osmolytes.

17. The method of claim 7 , wherein the redox component comprises one or more of glutathione-reduced, glutathione-oxidized, cysteine, cystine, cysteamine, cystamine and beta-mercaptoethanol.

18. The method of claim 1 or 7 , further comprising the step of washing the separation matrix with a regeneration reagent.

19. The method of claim 18 , wherein the regeneration reagent is one of a strong base or a strong acid.

20. The method of claim 19 , wherein the strong acid is phosphoric acid.

21. The method of claim 19 , wherein the strong base is sodium hydroxide.

22. The method of claim 18 , wherein the regenerating comprises washing the separation matrix with a solution comprising one or both of a chaotrope present at a concentration of 4-6 M and a reductant.

23. The method of claim 22 , wherein the chaotrope is one of urea, dimethyl urea, methylurea, ethylurea, and guanidinium.

24. The method of claim 22 , wherein the reductant is one of cysteine, dithiothreitol (DTT), beta-mercaptoethanol and glutathione.

25. The method of claim 18 , wherein the regenerating comprises washing the separation matrix with a solution comprising 50 mM Tris, 10 mM citrate, 6 M urea, 50 mM dithiothreitol (DTT) at pH 7.4.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 3, 2010
From: SHULTZ, JOSEPH EDWARD; HART, ROGER
To: AMGEN INC.
Reel/Frame 024779/0564 →
Continuity (2)
Provisional Application 61220477 · Jun 25, 2009
Related Publication 20100331526A1 · Dec 30, 2010